RNAC NASDAQ
Cartesian Therapeutics, Inc.
1W: -0.7%
1M: -18.9%
3M: -28.8%
YTD: +8.9%
1Y: -28.1%
3Y: -78.5%
5Y: -94.3%
$7.36
+0.14 (+1.94%)
Weekly Expected Move ±4.3%
$7
$7
$7
$8
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-10-25
Earliest Filing
2024-03-05
Latest Filing
partner: 7
investor: 2
target: 1
Counterparties (Filed by RNAC)
10 relationshipsCompanies named in RNAC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| 7495 RP, LLC | — | partner | Cartesian Therapeutics, Inc. entered into a lease agreement for manufacturing and office space. | 2024-03-05 | View |
| Cartesian Therapeutics, Inc. | RNAC | target | Target company acquired by Selecta Biosciences, Inc. in a merger agreement dated November 13, 2023. | 2023-11-13 | View |
| Sobi License | — | partner | Swedish Orphan Biovitrum AB (publ.) is identified as the counterparty to the Company's License and Development Agreement | 2023-11-13 | View |
| Audentes Therapeutics, Inc. | — | partner | Counterparty to the Company's License and Development Agreement (referred to as the 'Astellas Agreement') referenced in | 2023-11-13 | View |
| Genovis AB (publ.) | — | partner | Counterparty to the Company's Exclusive License Agreement referenced in the Contingent Value Rights section. | 2023-11-13 | View |
| TAS Partners, LLC | — | investor | Investor in the Securities Purchase Agreement (PIPE) entering into a transaction with the Company for Series A Preferred | 2023-11-13 | View |
| Seven One Eight Three Four Irrevocable Trust | — | investor | Investor in the Securities Purchase Agreement (PIPE) entering into a transaction with the Company for Series A Preferred | 2023-11-13 | View |
| Swedish Orphan Biovitrum AB (publ.) | — | partner | Amendment to License and Development Agreement granting exclusive license for manufacturing and transferring contracts/e | 2023-10-31 | View |
| SVB Leerink LLC | — | partner | Sales agent for at-the-market equity offering program | 2021-10-25 | View |
| Jefferies LLC | JEF | partner | Former sales agent for at-the-market equity offering program | 2021-10-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-17 | Shareholder Vote | View | |
| 2026-06-09 | Regulation FD; Exhibits | View | |
| 2026-05-26 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Officer/Director Change; Regula | Agreement | View |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-03-30 | Officer/Director Change | View | |
| 2026-03-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-18 | Departure/Election of Directors; Appointment of Officers; Amendment to Code of Ethics; Regulation FD | View | |
| 2025-11-13 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-10-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-08 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-16 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-30 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-29 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR